3FDA. Guidance for industry ANDAs:impurities in drug substances [S].Nov. 1999. 被引量：1
4FDA. Guidance for industry Court decisions, ANDAs approvals, and 180-day exclusivity under the Hatch-Waxman amendments to the federal food, drug and cosmetic act[ S]. Mar. 2000. 被引量：1
2LODEKER D, BRUNKLAUS G. NMR crystallography of ezetimibe co-crystals [ J ]. Solid State Nucl. Magn. Re-son. ,2015,65(SI) :29-40. 被引量：1
3SHIMPI M R, CHILDS S L, BOSTROMC D, et al. New cocrystals of ezetimibe with L-proline and imidazole [J]. Cryst. Eng. Commum. ,2014,16(38) :8 984-8 993. 被引量：1
4SUGANDHA K, KAITY S, MUKHERJEE S, et al. Solu- bility enhancement of ezetimibe by a cocrystal engineering technique [J]. Cryst. Growth Des. , 2014,14 ( 9 ) : 4 475- 4 486. 被引量：1
5MULYE S P, JAMADAR S A, POONAM S, et al. Im- provement in physicochemical properties of ezetimibe using a crystal engineering technique [J]. Powder Techn- ol. ,2012,222(2 012) :131-138. 被引量：1
6SWAMY G Y S K,RAVIKUMAR K,WADHWA L K,et al. ( 2R" , 3R * , 6S" ) -N, 6-bis ( 4-fluorophenyl ) -2-( 4- hydroxyphenyl ) -3,4,5,6-tetrahydro-2 H-pyran-3-carbox- amide [J]. Acta Crystallogr. Sect. E, 2005,61 ( 11 ) : 3 608-3 610. 被引量：1
7SNTA Z, KOTI J, SZOKE K, et al. Structure of the major degradant of ezetimibe [J]. J. Pharm. Biomed. Anal. , 2012,58(2 012) :125-129. 被引量：1
8BA3OV J,IMRAMOVSKY A, HJICEK J, et al. Kinet- ics and mechanism of the base-catalyzed rearrangement and hydrolysis of ezetimibe [J]. J. Pharm. Sci. ,2014,103 ( 8 ) :2 240-2 247. 被引量：1
10FILIP K,BANKOWSKI K, SIDORYK K, et al. Physico- chemical characterization of ezetimibe and its impurities [ J]. J. Mol. Struct. ,2011,991 (1/3) : 162-170. 被引量：1
